Chris Hollowood

Chris Hollowood

Chief Investment Officer

Chris is the Chief Investment Officer of Syncona Investment Management Ltd.

He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Freeline, SwanBio and Purespring and was also previously Chairman of retinal gene therapies Nightstar, which was sold to Biogen in 2019 for $877 million, and Gyroscope, which was sold to Novartis for up to $1.5 billion in 2022. 

Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.

Syncona portfolio companies

  • Freeline Therapeutics (Chair)
  • SwanBio Therapeutics (Chair)
  • Purespring Therapeutics (Chair)
Martin Murphy

Martin Murphy

Chief Executive Officer
Markus John

Markus John

Chief Medical Officer and Head of R&D
Edward Hodgkin

Edward Hodgkin

Senior Partner
Elisa Petris

Elisa Petris

Lead Partner
Magdalena Jonikas

Magdalena Jonikas

Lead Partner
Alex Hamilton

Alex Hamilton

Investment Partner
Michael Kyriakides

Michael Kyriakides

Investment Partner
Gonzalo Garcia

Gonzalo Garcia

Investment Partner
Alice Renard

Alice Renard

Investment Partner
Raghd Rostom

Raghd Rostom

Associate Partner
Lisa Bright

Lisa Bright

Commercial Advisor
Ben Woolven

Ben Woolven

Business Strategy and Operations Partner